Redcliffe Labs, a fast growing Noida based diagnostics network, has divested its fertility services arm, Crysta IVF, to Moon Care Private Limited the healthcare subsidiary of the MMG Group. The strategic move, announced on April 9, 2026, allows Redcliffe Labs to concentrate fully on expanding its core preventive and advanced diagnostic services across India.
Glimpse:
On April 9, 2026, Redcliffe Labs announced the sale of its Crysta IVF business to Moon Care Private Limited. The transaction was exclusively advised by Alvarez & Marsal. Crysta IVF will continue operations with the same team and leadership under the new owner, while Redcliffe Labs plans to accelerate its growth in technology driven diagnostics, increase testing volumes, and strengthen preventive healthcare initiatives. This marks Moon Care’s (and MMG Group’s) entry into the healthcare sector with a focus on making fertility care more accessible and technology enabled.
Redcliffe Labs, recognized as one of India’s fastest growing diagnostic healthcare networks with a strong emphasis on preventive care, has strategically divested its fertility services business known as Crysta IVF. The buyer is Moon Care Private Limited, the dedicated healthcare arm of the MMG Group. The announcement came on April 9, 2026, and the deal was facilitated exclusively by global professional services firm Alvarez & Marsal.
The divestment enables Redcliffe Labs to sharpen its focus on its primary strength delivering accessible, accurate, and affordable diagnostic solutions. The company intends to use this opportunity to speed up expansion plans, boost overall testing volumes, and deepen its commitment to preventive healthcare aimed at enabling early detection and adding healthier years to people’s lives. Redcliffe Labs will now channel all resources toward building a robust diagnostics ecosystem powered by technology.
Under the new ownership, Crysta IVF is expected to maintain operational continuity with its existing team and leadership intact. Moon Care plans to provide strategic support to grow the business further, with an emphasis on expanding access to high-quality reproductive health services nationwide. The platform has already earned the trust of thousands of families, and the new owners aim to enhance patient experience, improve clinical outcomes, and integrate more advanced technology into fertility treatments.
This transaction represents the MMG Group’s first major step into the healthcare sector. Chairman Sanjeev Agarwal highlighted the group’s ambition to create meaningful impact by improving access and outcomes at scale through specialized care.
“Our priority has always been to build a strong, accessible diagnostics ecosystem rooted in preventive healthcare with the goal of adding healthier years to people’s lives. This divestment allows us to sharpen that focus even further.”
By
HB Team
Related News
